An observational study in Covid19, sponsored by Federico II University. Completed at 1 site in Italy. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-19.
Sponsored by Federico II University · Observational
This study evaluates the retinal vascular features using optical coherence tomography angiography in patients that have been affected by COVID-19.
To investigate the potential role of optical coherence tomography angiography in identifying the changes in retinal vessel density in patients that have been affected by COVID-19.
The optical coherence tomography angiography represents a noninvasive diagnostic technique that allows a detailed analysis of retinal vascular features.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 40 is below the median of 260 across 3,135 observational studies indexed under COVID-19.
Browse COVID-19 studies →Federico II University is the lead sponsor of 356 studies on the registry; 60 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The participans were older than 18 years with previous diagnosis of COVID-19. They did not present other ophthalmological diseases.
Exclusion Criteria:
The patients with previous diagnosis of COVID19
Diagnostic Test: Optical coherence tomography angiography
Healthy subjects without actual and previous ocular diseases
Diagnostic Test: Optical coherence tomography angiography
Each subject underwent optical coherence tomography angiography to evaluate the retinal vessel density.
The measurements of retinal features in patients with previous diagnosis of COVID19, using optical coherence tomography angiography.
The parameter analyzed by optical coherence tomography angiography was: retinal vessel density
Time frame: one month
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Federico II University